1. "2024"
Formats
  1. Journal Article (2329)
  2. Meeting Abstract (1694)
  3. Review (589)
  4. Editorial (305)
  5. Book Section (98)
  6. Correspondence (92)
  7. Guidelines (90)
  8. Research Letter (89)
  9. Miscellaneous (55)
  10. Conference Paper (33)
  11. Book Whole (3)
Groups
  1. Department of Medicine (2141)
  2. Solid Tumor Oncology Division (1382)
  3. Sloan Kettering Institute Postdocs (1038)
  4. Surgery (984)
  5. Graduate Medical Education (883)
  6. GSK Faculty (868)

More Groups

People
  1. Eileen O'Reilly (75)
  2. Saad Usmani (75)
  3. Edward Christopher Dee (70)
  4. Nadeem Abu-Rustum (70)
  5. Alice Wei (69)
  6. T Peter Kingham (68)

More People

Years
  1. 2024 (5377)
Publications
  1. Journal of Clinical Oncology (521)
  2. International Journal of Radiation Oncology, Biology, Physics (186)
  3. Blood (161)
  4. Annals of Oncology (147)
  5. Annals of Surgical Oncology (131)
  6. Laboratory Investigation (91)

More Publications

Publishers
  1. Elsevier Inc. (784)
  2. American Society of Clinical Oncology (580)
  3. Nature Publishing Group (384)
  4. Springer (357)
  5. Oxford University Press (347)
  6. Elsevier Science, Inc. (256)

More Publishers

Results (5377)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Polygenic risk score associations with immune checkpoint inhibitors related endocrine toxicity
    Meeting Abstract

    Thorball, C. W.; Quandt, Z.; Saha, A.; Yao, L.; Midda, P.; Xu, Y.; Bejan, C. A.; Hodel, F.; Stravodimou, A.; Shearer-Kang, E.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Development and validation of a 19-feature classifier that predicts response to neoadjuvant trastuzumab emtansine (T-DM1) in breast cancer patients
    Meeting Abstract

    Pareja, F.; Paul, E. D.; Huraiová, B.; Valková, N.; Matyasovská, N.; Gábrisová, D.; Gubová, S.; Ignacáková, H.; Ondris, T.; Bendíková, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Characteristics of real-world (RW) NATALEE and monarchE eligible populations: A US electronic health records (EHR) database analysis
    Meeting Abstract

    Tarantino, P.; Rugo, H. S.; Curigliano, G.; O'Shaughnessy, J.; Janni, W.; Jhaveri, K.; Mouabbi, J. A.; Brufsky, A. M.; Hamilton, E. P.; Oregan, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Association of a blood T cell fitness gene signature with clinical benefit from ImmTAC bispecific T cell engagers
    Meeting Abstract

    Sacco, J. J.; Carvajal, R. D.; Hamid, O.; Kirk, P. B.; Collins, L.; Butler, M. O.; Shoushtari, A. N.; Hassel, J. C.; Ikeguchi, A. P.; Hernandez-Aya, L.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • The role of CTNNA1 truncating variants in hereditary diffuse gastric cancer (HDGC)
    Meeting Abstract

    Lobo, S.; Dias, A.; Ferreira, M.; Herrera-Mullar, J.; Svrcek, M.; Hueneburg, R.; Moreira, L.; Tinschert, S.; Boussemart, L.; Balmaña, J.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
    Meeting Abstract

    Macarulla Mercade, T.; Harding, J. J.; Pant, S.; Wu, X.; Garfin, P.; Okusaka, T.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Durvalumab (D) as consolidation therapy in limited-stage SCLC (LS-SCLC): Outcomes by prior concurrent chemoradiotherapy (cCRT) regimen and prophylactic cranial irradiation (PCI) use in the ADRIATIC trial
    Meeting Abstract

    Senan, S.; Spigel, D. R.; Cho, B. C.; Laktionov, K.; Zenke, Y.; Lee, K. H.; Wang, Q.; Navarro Mendivil, A. F.; Buchmeier, E. L.; Sezgin Goksu, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA)
    Meeting Abstract

    Powles, T. B.; van der Heijden, M. S.; Galsky, M. D.; Al-Ahmadie, H.; Meeks, J. J.; Nishiyama, H.; Vu, T. Q.; Antonuzzo, L.; Wiechno, P.; Atduev, V.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Tivozanibenivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study
    Meeting Abstract

    Choueiri, T. K.; Motzer, R. J.; Beckermann, K.; Barthelemy, P.; Iacovelli, R.; Emambux, S.; Molina Cerrillo, J.; Garmezy, B.; Coelho Barata, P. M.; McKay, R. R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Updated efficacy and safety from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)
    Meeting Abstract

    Riely, G. J.; Ahn, M. J.; Clarke, J.; Dagogo-Jack, I.; Felip, E.; Gelsomino, F.; Goldman, J. W.; Hussein, M.; Johnson, M. L.; Morgensztern, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save